Mitochon Pharmaceuticals » Logo
Mitochon Pipeline
Mitochon Pipeline
Preclinical Efficacy
IND Enabling Activities
Phase I
Phase II

Parkinson’s Disease

No known genetic cause.
Movement issues, depression and later stages dementia.
Mouse Model: 6-OHDA injected into the right striatum.
0.5mpk MP101 and 8mpk MP201 was provided orally (q.d.) for 2 weeks.
The dopaminergic neurons are slowly destroyed over the course of two weeks and mice are then tested on a constant speed rotarod for duration (3-min max).
Work done at National Institute on Aging.

Our Data Shows:

Increased cortical sparing (p <0.01; 38% lesion spared).
Improved cognitive outcome (p<0.05).

Kishimoto, Y., et al., A mitochondrial uncoupler prodrug protects dopaminergic neurons and improves functional outcome in a mouse model of Parkinson's disease. Neurobiol Aging, 2020. 85: p. 123-130.

Study 2:  MP201 and MP101 (DNP) treatments reduce degeneration of substantia nigra dopaminergic neurons in the 6-OHDA mouse model of PD.

MP101 Significantly Reduces Oxidative Stress » Mitochon PharmaceuticalsMP101 Significantly Reduces Oxidative Stress » Mitochon Pharmaceuticals
**p<0.001 compared to the value for the control group.
#p<0.05, ##p<0.01 compared to the value for the placebo group.